Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
Trial ID or NCT#
Status
Purpose
This study is designed to answer whether patients with progressive IgA nephropathy, who receive Acthar (ACTH) gel injection at a dose of 80 units subcutaneously twice weekly for 6 months is effective in inducing improvement in proteinuria and renal function.
Official Title
An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
Eligibility Criteria
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Kshama R Mehta, Ph.D
650-736-1822
View on ClinicalTrials.gov